Farms.com Home   Ag Industry News

Farm2050 looks to help agricultural technology startup

Collective includes companies headed by Google Chairman Eric Schmidt

By Diego Flammini, Farms.com

Startups dedicated to agricultural technology (agtech) who need a financial boost in hopes their dreams become a reality can apply for an investment partnership with some heavy hitters in the agtech world.

Innovation Endeavours and Flextronics’ Lab IX, founded by Google Chairman Eric Schmidt, AGCO, DuPont, and others, make up Farm2050, an initiative focusing on robotics and data science to confront global food security and waste.

"(A hundred) years ago, we saw the Haber-Bosch process enable fertilizer development," said Innovation Endeavors Managing Partner Dror Berman, in a statement. "50 years ago, we saw the refrigerated truck facilitate the long-distance transport of perishables. And today, we're seeing the emergence of robotics and machine learning applied to agricultural practices.”

The obstacles the entrepreneurs face is intense. Berman estimates needing to feed more than 10 billion people by 2050. That’ll require a nearly 70% increase in food production.

“This is a tall order but also the type of challenge that technologists should be working to solve,” he said.

Farm2050 isn’t the only investment group to look at infusing the agricultural business sector.

In November, Kleiner Perkins Caufield and Byers invested in Farmers Edge out of Winnipeg, Manitoba, who specialize in precision agriculture.

"They uniquely integrate real-time satellite imagery and in-field telematics to maximize yield and minimize environmental footprint," said Kleiner Perkins' Brook Porter, in a statement. "Farmer's Edge is leading the current disruption around how crops are grown, and ultimately how crops are valued as traceability becomes an increasingly important factor in the food supply chain."
 


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.